IDT Australia, an ASX-listed pharmaceutical contract development and manufacturing organisation (CDMO), has announced the resignation of CEO Paul McDonald “with immediate effect”. According to a statement from the company on Thursday, current Independent Non-Executive Chair Mark Simari, who has been on the board since 2022, is now Executive Chair. The search for a new CEO will…
ASX-listed pharmaceutical contract development and manufacturing organisation (CDMO) IDT Australia has signed an MoU with oral drug and nutrient delivery business Gelteq, aimed at scaling up production on Gelteq’s products. According to a statement from IDT on Thursday, the MoU “establishes a framework for Gelteq to set up its base and develop a dedicated facility”…
Victoria has opened Australia’s first facility accredited to manufacture a targeted cancer treatment that significantly improves patient survival rates and quality of life. Industry and Advanced Manufacturing Minister Colin Brooks opened IDT Australia’s Ehrlich Bioconjugation Centre in Boronia on Monday. The centre is dedicated to producing Antibody Drug Conjugates for research and development, clinical and…
Pharmaceutical manufacturer IDT Australia has reported revenue for the quarter ended 30 September up 70 percent on the previous corresponding period to reach a two year high of $5.2 million. The Melbourne company said the results were encouraging and came on top of the it submitting proposals worth $24.7 million and securing $6.8 million in…
IDT Australia secures Sanofi contract Pharmaceutical development company IDT Australia has secured a follow on contract with pharma giant Sanofi Australia for preclinical formulation, development and manufacture of Sanofi’s messenger RNA (mRNA). The contract, worth up to $4 million, continues the company’s advancement of mRNA-based vaccine formulation, development and manufacture at IDT’s aseptic sterile injectables…
What were the five biggest stories of the week? Here’s what visitors to @AuManufacturing were reading. 5) Psychotropic medicines manufacturer bids for IDT Australia Psychotropic medicines manufacturer Mynd Bio Pty Ltd has made a surprise bid to acquire listed pharmaceutical developer, Melbourne-based IDT Australia. The bidder is part of a larger group which has already…
Psychotropic medicines manufacturer Mynd Bio Pty Ltd has made a surprise bid to acquire listed pharmaceutical developer, Melbourne-based IDT Australia. The bidder is part of a larger group which has already invested in a group of pharmaceutical companies that develop psychotropic medicines, planning to set up manufacturing in Portugal to tackle the European market. The…
IDT Australia to raise $7 million for mRNA vaccine production Pharmaceutical manufacturer IDT Australia is to raise $7 million a fully underwritten entitlement offer of fully paid ordinary shares to eligible shareholders. The funds raised will be used to fund capital expenditure relating to current and potential future works in the mRNA therapeutics field including…
The Victorian government has announced backing for pharmaceutical manufacturer IDT Australia to boost production of live-saving cancer treatments. IDT Australia will build a new facility in Boronia, Melbourne to manufacture Antibody Drug Conjugates (ADCs) which have the specificity of monoclonal antibodies and deliver chemotherapy agents to cancer tumor sites. ADCs are set to replace almost…
Pharmaceutical manufacturer IDT Australia has announced that it has been awarded a Victorian government grant to assist in the establishment of an Australian-first facility for oncology drugs. In an ASX statement on Monday, IDT said it has established relationships with Antibody-Drug-Conjugate (ADC) biotech companies, including a master services agreement with Japanese pharmaceutical company Nagase &…